Display options
Cite
Nett ST, Noble JA, Levin DL, et al. Biomarkers and genetics of brain injury risk in diabetic ketoacidosis: A pilot study. J Pediatr Intensive Care. 2014;3(2)doi: 10.3233/PIC-14091.
Nett, S. T., Noble, J. A., Levin, D. L., Cvijanovich, N. Z., Vavilala, M. S., Jarvis, J. D., & Flori, H. R. (2014). Biomarkers and genetics of brain injury risk in diabetic ketoacidosis: A pilot study. Journal of pediatric intensive care, 3(2), . https://doi.org/10.3233/PIC-14091
Nett, Sholeen T, et al. "Biomarkers and genetics of brain injury risk in diabetic ketoacidosis: A pilot study." Journal of pediatric intensive care vol. 3,2 (2014). doi: https://doi.org/10.3233/PIC-14091
Nett ST, Noble JA, Levin DL, Cvijanovich NZ, Vavilala MS, Jarvis JD, Flori HR. Biomarkers and genetics of brain injury risk in diabetic ketoacidosis: A pilot study. J Pediatr Intensive Care. 2014;3(2). doi: 10.3233/PIC-14091. PMID: 26097769; PMCID: PMC4472439.
Copy Download .nbib Format: NLM
Share it on

J Pediatr Intensive Care. 2014;3(2). doi: 10.3233/PIC-14091.

Biomarkers and genetics of brain injury risk in diabetic ketoacidosis: A pilot study.

Journal of pediatric intensive care

Sholeen T Nett, Janelle A Noble, Daniel L Levin, Natalie Z Cvijanovich, Monica S Vavilala, J Dean Jarvis, Heidi R Flori

Affiliations

  1. Department of Pediatric Critical Care Medicine, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH, USA.
  2. Children's Hospital Oakland Research Institute, Oakland, CA, USA.
  3. Department of Pediatric Critical Care Medicine, Children's Hospital and Research Center Oakland, Oakland, CA, USA.
  4. Department of Pediatric Critical Care Medicine, University of Washington Children's Hospital, Seattle, WA, USA.

PMID: 26097769 PMCID: PMC4472439 DOI: 10.3233/PIC-14091

Abstract

Diabetic ketoacidosis (DKA) is the primary cause of death for children with diabetes, especially when complicated by cerebral edema. Central nervous system (CNS) involvement is common, however the mechanism of, and predictors of CNS dysfunction/injury are largely unknown. In this observational pilot study, blood was collected from pediatric DKA patients at three time points (consent, 12 hr and 24 hr after beginning treatment), to test genetic markers, ribonucleic acid expression and plasma biomarkers reflecting inflammation (tumor necrosis factor-alpha [TNF-α], interleukin-6 [IL-6]) and cerebral dysfunction and/or possible injury (S100β, glial fibrillary acidic protein [GFAP]). Thirty patients were enrolled in the study. The average age was 11.3 yr, 73% were new onset diabetes and 53% were female. Forty percent exhibited abnormal mentation (Glasgow Coma Scale <15), consistent with CNS dysfunction. IL-6 and TNF-α were elevated in plasma, suggesting systemic inflammation. GFAP was measurable in 45% of patients and correlated positively with GCS. Only two patients had detectable levels of S100β. In conclusion, children with DKA often present with evidence of acute neurologic dysfunction or injury. We have demonstrated the feasibility of exploring genetic and biochemical markers of potential importance in the pathophysiology of CNS dysfunction and/or possible injury in DKA. We have identified IL-6, TNF-α and GFAP as potentially important markers for further exploration. A larger, follow-up study will help to better understand the extent and type of CNS injury in DKA as well as the mechanism underlying this dysfunction/injury.

Keywords: Cerebral edema; diabetic ketoacidosis; genetic biomarkers; pilot; vanguard

References

  1. Diabetes Care. 2001 May;24(5):956-7 - PubMed
  2. J Neurotrauma. 2013 Mar 1;30(5):324-38 - PubMed
  3. Arch Dis Child. 1999 Oct;81(4):318-23 - PubMed
  4. J Pediatr. 2005 May;146(5):688-92 - PubMed
  5. Pediatr Diabetes. 2007 Oct;8 Suppl 6:6-14 - PubMed
  6. Pediatr Crit Care Med. 2010 May;11(3):332-8 - PubMed
  7. Am J Physiol Endocrinol Metab. 2014 May 1;306(9):E1077-84 - PubMed
  8. Acta Paediatr. 1998 May;87(5):537-41 - PubMed
  9. J Neurotrauma. 2004 Nov;21(11):1553-61 - PubMed
  10. Neurochem Res. 2007 Apr-May;32(4-5):905-15 - PubMed
  11. Diabetes. 2004 Aug;53(8):2079-86 - PubMed
  12. N Engl J Med. 2001 Jan 25;344(4):302-3 - PubMed
  13. Clin Chem Lab Med. 2003 Oct;41(10):1335-9 - PubMed
  14. J Pediatr. 1992 Jul;121(1):68-74 - PubMed
  15. Diabetes Care. 2004 Jul;27(7):1541-6 - PubMed
  16. Dev Neurosci. 2010;32(5-6):396-405 - PubMed
  17. Neurology. 2010 Nov 16;75(20):1786-93 - PubMed
  18. Diabetes Care. 1990 Jan;13(1):22-33 - PubMed
  19. Eur Cytokine Netw. 2005 Dec;16(4):277-81 - PubMed
  20. Neurochem Res. 2000 Oct;25(9-10):1439-51 - PubMed
  21. Pediatr Crit Care Med. 2008 May;9(3):320-9 - PubMed
  22. N Engl J Med. 2001 Jan 25;344(4):264-9 - PubMed
  23. Microcirculation. 2013 Aug;20(6):534-43 - PubMed
  24. Clin Chem Lab Med. 2008;46(9):1296-9 - PubMed
  25. Crit Care Med. 2006 Aug;34(8):2217-23 - PubMed
  26. Clin Immunol. 2003 Sep;108(3):175-81 - PubMed
  27. Pediatr Crit Care Med. 2004 Jan;5(1):53-7 - PubMed
  28. Neurocrit Care. 2014 Jun;20(3):427-35 - PubMed
  29. Circulation. 2003 Jul 1;107(25):3199-203 - PubMed
  30. Brain Res. 2009 Feb 13;1254:138-48 - PubMed
  31. Pediatr Crit Care Med. 2013 Jan;14(1):19-26 - PubMed
  32. Pediatrics. 2004 Feb;113(2):e133-40 - PubMed
  33. Diabetes Care. 2003 Apr;26(4):1265-9 - PubMed
  34. Pediatrics. 2013 Apr;131(4):754-66 - PubMed
  35. Nat Clin Pract Neurol. 2006 Feb;2(2):78-86 - PubMed
  36. Neurosci Lett. 2012 Feb 29;510(2):110-4 - PubMed
  37. Pediatr Neurol. 1999 Oct;21(4):721-7 - PubMed
  38. Pediatr Diabetes. 2006 Apr;7(2):73-4 - PubMed
  39. Arch Dis Child. 2001 Jul;85(1):16-22 - PubMed
  40. J Pediatr. 2010 Jan;156(1):109-14 - PubMed
  41. Pediatr Diabetes. 2006 Apr;7(2):75-80 - PubMed
  42. Diabetes Care. 2011 Sep;34(9):1891-6 - PubMed
  43. Chang Gung Med J. 2005 Jan;28(1):24-30 - PubMed

Publication Types

Grant support